| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10965881 | Vaccine | 2013 | 7 Pages |
Abstract
rHPIV3cp45 was immunogenic and well-tolerated in seronegative young children. A second dose administered 6 months after the initial dose was restricted in those previously infected with vaccine virus; however, the second dose boosted antibody responses and induced antibody responses in two previously uninfected children.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Janet A. Englund, Ruth A. Karron, Coleen K. Cunningham, Philip LaRussa, Ann Melvin, Ram Yogev, Ed Handelsman, George K. Siberry, Bhavanji Thumar, Elizabeth Schappell, Catherine V. Bull, Helen Y. Chu, Anne Schaap-Nutt, Ursula Buchholz, Peter L. Collins,